Ownership history in AIA Group Ltd Β· 24 quarters on record
This page tracks every 13F SEC filing in which AIA Group Ltd reported a position in HUTCHISON CHINA MEDITECH LTD (HCM). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π AIA Group Ltd underperformed the S&P 500 by β13.2% annually on this HCM position. Timing score: 30% (3/10 decisions correct). Average cost basis: $25.86. Maximum drawdown during holding period: β77.4%.
β Significantly underperformed the S&P 500 by 13.2% ann.
23 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
3 of 10 add/trim decisions correct
Best entry: $8.86 (2022 Q3) Β· Worst: $32.02 (2020 Q4)
πͺ Held through 2 major drawdowns (>20%).
5 adds Β· 5 trims. Bought during 2 of 12 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.06% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size